Key Points
-
The disposition involved 6,490 shares worth about $183,000 at a price of $28.15 per share on August 14.
-
All shares were withheld by the issuer to cover tax obligations following the quarterly vesting of restricted stock units (RSUs).
-
Given the nature of the filing, the transaction does not reflect the insider’s view on the company’s valuation or future prospects.
- 10 stocks we like better than Hims & Hers Health ›
Irene Becklund, the chief accounting officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a non-discretionary disposition of 6,490 shares in this transaction, accordin to an SEC Form 4 filing.
Transaction summary
MetricValueShares sold6,490Transaction value$183,000Post-transaction shares (directly held)13,985Post-transaction value$393,677.75
Transaction value based on SEC Form 4 weighted average sale price ($28.15); post-transaction value based on the August 14 market close ($28.15).
Key questions
- What were the underlying mechanics of this transaction?The disposition resulted from the vesting of restricted stock units awarded under a service-based vesting schedule that began in June 2023, with shares withheld automatically to satisfy tax withholding obligations.
- What is the insider’s remaining equity exposure?Following the completion of this transaction, Becklund maintains a direct position of 13,985 shares and also holds additional derivative securities, which include both vested and unvested awards.
- How has the stock performed leading up to this filing?As of the August 14 transaction date, the company’s shares had recorded a 1-year return of -40%.
- What was the market valuation at the time of execution?The transaction was executed at $28.15 per share, matching the market close on the date of the transaction, while the stock was priced at $28.61 as of the August 17 market close.
Company Overview
MetricValueShare Price (as of market close 2026-08-17)$28.61Market Capitalization$6.4 billionRevenue (TTM)$2.6 billionNet Income (TTM)-$142.0 million
Company Snapshot
- Hims & Hers operates a comprehensive digital health platform that delivers prescription medications, over-the-counter drugs, medical devices, cosmetics, and dietary supplements directly to consumers through its website and mobile application.
- The company generates revenue through a direct-to-consumer model by connecting patients with licensed medical professionals for virtual consultations and facilitating the distribution of pharmaceutical and wellness products.
- The platform primarily serves consumers seeking convenient access to healthcare services and products, with a focus on individuals managing chronic conditions and those seeking preventive care and wellness solutions.
Hims & Hers Health operates as a leading digital health platform with a $6.4 billion market capitalization and $2.6 billion in TTM revenue, positioning it as a significant player in the telehealth and direct-to-consumer pharmaceutical space. The company’s integrated model combines virtual medical consultations with direct product fulfillment, creating a vertically aligned ecosystem that enhances customer retention and lifetime value. Despite current net losses of $142.0 million TTM, the company’s scale and market presence reflect investor confidence in the digital health transformation and the secular shift toward consumer-directed healthcare delivery.
What this transaction means for investors
This filing carries a different weight than others from Hims insiders this week because Becklund is leaving the firm. Hims & Hers announced on July 17 that its chief accounting officer of seven years will depart effective October 9, staying on afterward as an advisor while the company searches for a permanent replacement. CFO Yemi Okupe, who’s taking over the CAO role in the interim, called her a “trusted leader” whose work shaped the company’s financial reporting through its IPO and international expansion.
None of that makes this specific tax-withholding sale meaningful on its own. But it might explain why her remaining direct stake, just 13,985 shares, is so much smaller than her peers’, given that someone six weeks from an exit probably isn’t going to be accumulating.
The more important question for investors isn’t Becklund’s shares; it’s whether the finance function holds up through the transition. She helped build the reporting infrastructure at a company that just closed its largest acquisition ever and is guiding to $3.1 billion to $3.3 billion in 2026 revenue. Okupe now inherits that job on top of his own as the company navigates strong growth and a murky regulatory landscape.
Should you buy stock in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,381,040!*
Now, it’s worth noting Stock Advisor’s total average return is 969% — a market-crushing outperformance compared to 215% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 19, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy.
